Background-Echocardiographic screening of families with dilated cardiomyopathy has identified a subgroup of asymptomatic relatives with left ventricular enlargement (LVE). The prognostic significance of LVE in this setting is incompletely understood. Methods and Results-We evaluated 457 asymptomatic relatives in 128 dilated cardiomyopathy families and identified 110 individuals (24%) with LVE. Serial echocardiograms in 72 untreated LVE relatives showed that 9 individuals (13%) had development of dilated cardiomyopathy over 10 to 152 months (median, 52). Thirty LVE relatives and 30 age-and sex-matched healthy control subjects were evaluated using 2-dimensional and M-mode echocardiography, tissue Doppler imaging, noninvasive pressure-volume assessment, exercise stress echocardiography, and brain natriuretic peptide levels. LVE relatives showed mild defects of systolic and diastolic LV function, with normal filling pressures and exercise-induced increments in systolic contraction in most cases. LV dimensions and fractional shortening most effectively differentiated LVE relatives from control subjects, with other functional indices lacking additive discriminative value. In a receiver operating characteristics analysis, the area under the curve for LV end-diastolic diameter (% predicted) was 0.96 (PϽ0.001). LV end-diastolic diameter (% predicted) Ͼ116% or LV end-diastolic diameter (% predicted) 112% to 116%ϩfractional shortening Յ29% had high sensitivity (100%) and specificity (93%) for LVE relatives and identified 8 of 9 progressors. Conclusions-LVE is a common finding in asymptomatic relatives in dilated cardiomyopathy families and can be a marker of preclinical cardiomyopathy. Assessment of LV size and contractile function is required for differentiating between pathological and physiological causes of LVE and may help to identify those at risk of disease progression. (Circ Cardiovasc Genet. 2011;4:342-348.)
D ilated cardiomyopathy (DCM) is a common cause of heart failure and a significant health and economic burden. There is increasing evidence of a substantial heritable component to DCM and at least 20% to 35% individuals with "idiopathic" DCM have familial disease. 1, 2 Nearly 40 chromosomal loci and disease genes have been identified to date. 3 Presymptomatic diagnosis of early disease provides an opportunity for preventative intervention but reliable methods for detection of individuals at risk are required. Ideally, family genotyping would enable genotype-positive individuals to be identified before the onset of symptoms. Because of the costs and time involved in screening large numbers of genes and the low yield (Ͻ30%) of finding mutations, genotype results are not available for most families. Hence, assessment of the clinical phenotype remains a cornerstone of family management.
Clinical Perspective on p 348
Systematic echocardiographic screening of asymptomatic relatives in DCM families has identified a subgroup of individuals who have abnormalities of left ventricular (LV) size or function that do not fulfill criteria for DCM. 4 -8 Isolated LV enlargement (LVE) has been observed most frequently, with a lesser number of individuals having normal LV size and depressed fractional shortening (dFS). It has been proposed that these echocardiographic changes represent preclinical stages of disease. At least one-third of cases do have latent cardiomyopathy, indicated by myocardial histological changes, reduced maximal exercise oxygen consumption, or cardiac autoantibodies. 5,9 -12 However, LVE may also result from unrelated pathologies or physiological variation, particularly in young, fit individuals engaged in competitive sporting activity. Differentiating family members with true early DCM from those with "athlete's heart" poses a major challenge with significant management implications.
The major objective of this study was to evaluate the natural history of LVE and the role of various indices for assessment of myocardial function. We used diagnostic techniques that have been proposed to be more sensitive or specific indicators of LV functional defects than standard assessment by 2-dimensional and M-mode echocardiography, including tissue Doppler imaging, 13 noninvasive determination of the preload recruitable stroke work (PRSW) relationship, 14 -16 exercise stress echocardiography, 17 and plasma levels of brain natriuretic peptide (BNP). 18 Our data confirm the prognostic significance of LVE as a marker of early disease in familial DCM and suggest a practical approach to the investigation of asymptomatic family members.
Methods

Subjects
Probands from 128 kindreds with suspected familial DCM were identified from St Vincent's Hospital and by physician referral (Table 1) . Family members Ͼ16 years of age were invited to undergo clinical evaluation, 12-lead ECG, and transthoracic echocardiography. M-mode echocardiographic dimensions were corrected for age and body surface area according to the Henry formula, 19 with LV end-diastolic diameter (LVEDD) expressed as a percentage of predicted diameter as follows: predicted LVEDDϭ(45.3ϫbody surface area 0.3 )Ϫ(0.03ϫage)Ϫ7.2. DCM was defined as LVEDD (% predicted) Ͼ112% and LV fractional shortening (LVFS) Ͻ25%. Familial DCM was defined as having 2 or more first-degree relatives with DCM that was unexplained by other inherited cardiac or systemic disorders. In asymptomatic relatives, LVE was defined as LVEDD (% predicted) Ͼ112%, and dFS was defined as LVFS Ͻ25%. 5, 8, 12 The control group comprised 30 healthy volunteers who had no history of cardiovascular disease. All subjects provided informed written consent, and protocols were approved by the institutional Human Research Ethics Committee.
Longitudinal Observational Study
Relatives were followed with serial echocardiograms. For relatives who had been screened before study recruitment, the follow-up period was taken from the first available echocardiogram. The duration of follow-up was determined as the time to disease progression, or commencement of treatment for DCM prophylaxis, or the most recent echocardiogram. Disease progression was defined by a new onset of contractile dysfunction (LVFS Ͻ25%) or worsening of contractile dysfunction (if baseline LVFS was Ͻ25%).
Phenotype Assessment
Transthoracic echocardiography was performed according to American Society for Echocardiography guidelines. In addition to LVEDD (% predicted) Ͼ112%, 2 alternative methods for assessment of LV size were evaluated. LV dilation was defined by LVEDD Ͼ2.7 cm/body surface area (expressed as m 2 ) (National Heart, Lung, and Blood Institute [NHLBI] standard) 20 or LVEDD above heightand sex-adjusted 95th and 97.5th percentile limits (Framingham standard). 21 Peak velocity of early (E) and late (A) diastolic filling and isovolumic contraction and relaxation times were measured from mitral inflow velocities; ejection time was measured from LV outflow velocity tracings. The myocardial performance index index was derived with the use of the isovolumic contraction, isovolumic relaxation, and ejection times. 22 Systolic (S), early (EЈ), and late (AЈ) diastolic myocardial tissue Doppler velocities were recorded at the septal and lateral margins of the mitral annulus. The PRSW relationship was determined from noninvasive peripheral arterial pressure waveforms and echocardiographically derived on-line LV volume, 23 using the linear regression equation: stroke workϭM W (end-diastolic volumeϪV W ), where M W is the slope and V W is the volume axis intercept. 14 -16 Data were obtained at rest and with variable preload induced by the Valsalva maneuver. Exercise stress echocardiography was performed with the use of the Bruce protocol. LV end-diastolic and end-systolic areas were measured in the short-axis view at rest and immediately after peak exercise. NT-pro BNP levels were measured in plasma samples by electrochemiluminescence with the use of the Elecsys II proBNP immunoassay (Roche Diagnostics).
Statistical Analysis
Differences between progressors and nonprogressors and between LVE cases and control subjects were evaluated by using maximum likelihood repeated-measures linear or logistic regression, accounting for the clustering within families (Stata 10, StataCorp LP, College Station, TX). The clustering within families was modeled with the use of a random effect that was assumed to be independent and identically normally distributed with mean zero and constant variance. Receiver operating characteristic analysis was performed with the use of PASW Statistics 18 (IBM Corp, Somers, NY). A 2-tailed probability value Ͻ0.05 was considered statistically significant. Data are reported as meanϮSD.
Results
Prevalence and Outcome of Asymptomatic Echocardiographic Changes
Four hundred fifty-seven asymptomatic relatives from 128 DCM families were evaluated ( Figure 1 and Table 1 ). Eighteen relatives (4%) had unsuspected DCM and were commenced on treatment. One hundred fifteen relatives †Calf tenderness during exercise and raised creatine kinase levels found in 2 affected individuals in 1 family. No individuals in any family had clinical signs of skeletal muscle weakness or wasting. Creatine kinase levels were not systematically assessed in all cases.
‡Presumptive mode of inheritance is based on distribution of affected individuals in family pedigrees.
§Novel mutations (unpublished) were present in 4 families. Of 23 genotyped family members, 13 individuals were genotype-positive (DCM, 3; left ventricular enlargement, 5; obligate carrier, 1) and 10 individuals were genotypenegative (all phenotypically normal).
(25%) from 54 families had echocardiographic changes, with LVE in 110 relatives and dFS in 5 relatives. One hundred five relatives (100 LVE, 5 dFS) were followed prospectively over 10 to 202 months (median, 55), with 16 individuals (15%; 15 LVE, 1 dFS) having DCM. Seventy-four relatives (72 LVE, 2 dFS) had serial echocardiograms available during periods in which they received no cardiovascular medications. Thirtyseven individuals (34 LVE, 3 dFS) were receiving treatment for some or all of the follow-up period, including 6 LVE relatives who crossed over from the no-treatment group.
Natural History of LVE
The natural history of LVE was further evaluated in the subgroup of 72 relatives who were followed in the absence of treatment ("natural history" cohort, Figure 1 ). Nine relatives (13%) showed disease progression over follow-up periods ranging from 10 to 152 months (median, 52), including a 17-year-old boy with DCM who required heart transplantation. Baseline clinical and echocardiographic parameters were compared between those who progressed and those who did not ( Table 2 ). "Progressors" were relatively younger than "nonprogressors"; however, the mean age at DCM diagnosis in family members of progressors (42Ϯ16 years, nϭ37) was similar to the study probands overall (Table 1 ). Our findings are in keeping with recent data suggesting that screening of asymptomatic family members can identify at-risk individuals at an earlier stage of disease. 24 There were no differences in mean values for LVEDD, LVEDD (% predicted), or LVESD at study entry between progressors and nonprogressors.
Assessment of LV Dilation
Previous studies of early disease have focused on individuals with and without LVE within families, and the extent to which similar changes might be present in healthy control subjects has not been considered. To better characterize the LVE phenotype, we studied 30 consecutive LVE relatives who agreed to undergo further more detailed echo evaluation and 30 age-and sex-matched control subjects. None of these LVE relatives was a progressor. By design, all LVE subjects had LVEDD (% predicted) Ͼ112%, but, unexpectedly, 11 of 30 healthy control subjects also fell within this range. A higher cutoff, Ͼ118%, proposed by Baig et al, 5 had greater stringency, identifying 23 LVE relatives and 2 control subjects. In a receiver operating characteristic analysis, the area under the curve for LVEDD (% predicted) was 0.96 (PϽ0.001, Figure 2 ). LVEDD (% predicted) Ͼ116% gave the highest sensitivity (0.93) and specificity (0.93) and was found in 28 relatives and 2 control subjects. We compared LVEDD (% predicted) with 2 alternative methods for normalization of LV size. 20, 21 The NHLBI standard identified 21 LVE relatives and 13 control subjects, whereas the Framingham standard identified 24 LVE relatives and 2 control subjects at the 95th percentile and 19 LVE relatives and 1 control at the 97.5th percentile. The area under the curve for the NHLBI and Framingham 95th percentile standards were 0.75 (Pϭ0.001) and 0.95 (PϽ0.001), respectively ( Figure 2 ). These data indicate that LVEDD (% predicted) and the Framingham standards are superior to the NHBLI standard and have similar efficacy overall. Of the criteria evaluated, LVEDD (% predicted) Ͼ116% most effectively differentiated family members and control subjects.
Comparison of LV Function in LVE Relatives and Control Subjects
To determine whether preclinical defects of myocardial function are present in LVE relatives, a range of parameters were evaluated and compared with control subjects (Table 3) . At rest, LVE relatives had increased end-diastolic and endsystolic LV dimensions and lower LVFS, as well as lower peak E-wave velocities, lower peak and longer time to peak S-wave velocities, and higher myocardial performance index. Although there was a trend toward lower slope (M W ) and higher intercept (V W ) of the PRSW relationship in LVE relatives, both of which are indices of reduced contractility, 14 -16 there was a substantial scatter of data and the differences with control subjects did not achieve statistical significance. With exercise stress, LVE relatives achieved comparable peak heart rates but had lower systolic blood pressure and shorter exercise duration. LV cross-sectional areas before and after exercise were increased in LVE relatives, but the relative increment in fractional area change at peak exercise was equivalent to that in control subjects. Five LVE relatives and 2 control subjects had BNP levels that were higher than those of an age-and sex-determined reference range, but there were no differences in mean levels between the groups.
Predictive Value of Echocardiographic Indices
The sensitivity and specificity of indices of systolic and diastolic LV function were assessed by comparing the numbers of LVE relatives and control subjects who had values lying outside a limit defined Ϯ2 SD of the mean values in control subjects. Individual parameters had only weak to moderate sensitivity but generally high specificity ( Table 4 ). The cutoff value for LVEDD (% predicted) Ͼ122% defined by this method was less sensitive than LVEDD (% predicted) Ͼ116%. The combined criteria of LVEDD (% predicted) Ͼ116% or LVEDD (% predicted) 112% to 116%ϩLVFS Յ29 identified all 30 LVE (100%) relatives and 2 control subjects (sensitivity, 100%; specificity, 93%). Addition of other parameters had no incremental value for identifying LVE relatives. In the natural history cohort, 61 individuals met these criteria, including 8 of the 9 progressors.
Discussion
We found that LVE is common in asymptomatic relatives and that 1 in 10 individuals with LVE will progress to DCM within a 5-year period. LVE is also present in many normal individuals, highlighting the need for criteria to distinguish between pathological and physiological LV dilation. Our natural history data indicate that LVE alone incompletely identifies progressors and that assessment of LV size and contractile function is required for risk stratification. Although a variety of techniques for detecting preclinical cardiomyopathy have been proposed, standard 2-dimensional and M-mode echocardiography is an effective screening method for detection of early disease. These findings have implications for the clinical screening and follow-up of asymptomatic relatives in DCM families. The prevalence and natural history of LVE have been evaluated in several studies. 4 -8,12 In the largest series to date, Mahon et al 8 screened 767 asymptomatic relatives of 189 DCM probands and found 140 relatives (18%) with abnormal echocardiograms, including 119 relatives with LVE and 21 relatives with dFS. Eight of the 107 LVE relatives (8%) who were followed prospectively had development of DCM over a median 53-month period. In our cohort of 457 asymptomatic relatives in 128 DCM families, we found 115 of 457 asymptomatic relatives (25%) with abnormal echocardiograms, most of whom (nϭ110) had LVE. Nine of 72 untreated LVE individuals (13%) progressed to DCM over a median 52-month period. Our data are concordant with those of Mahon et al and show that a clinically significant number of asymptomatic relatives will deteriorate within 5 years after LVE is detected.
Given its prognostic significance, the reliability of methods used to define LVE is paramount. Diagnosis of LV dilation based on a laboratory reference range for LVEDD (eg, Ͼ56 mm) is relatively insensitive, particularly in women, and several different normalization formulae have been proposed that take into account factors such as age, sex, height, and body surface area. 19 -21 Normalization of LVEDD to BSA using the Henry formula has been recommended for clinical practice. 25 We selected LVEDD (% predicted) Ͼ112% because this is a frequently used criterion for LV dilatation and permits direct comparison with other early disease studies, including that of Mahon et al. 5, 8, 12 Baig et al 5 suggested that LVEDD (% predicted) Ͼ118% might be a better predictor of relatives at risk of DCM, whereas Hershberger et al 26 concluded that the Framingham standard was superior to LVEDD (% predicted) Ͼ112% or the NHLBI standard for detecting LVE. We concur with these findings but also show that LVEDD (% predicted) Ͼ116% gives even better discrimination between family members and control subjects.
Our natural history data do not support a direct relationship between LV size and disease progression in all cases, and some progressors had an only mild LVE together with LV systolic dysfunction at the initial screening study. These differences in primary manifestations of disease are likely to be explained, at least in part, by the underlying family gene mutation and demonstrate that LV size and function must be incorporated into risk assessment. A number of noninvasive techniques for detection of early myocardial dysfunction in familial DCM have been reported 5,9 -12 but a comprehensive comparative analysis has not been performed. Our echocardiographic studies provide insights into myocardial perfor- mance in LVE relatives as well as the sensitivity and specificity of various functional parameters.
The majority of LVE relatives had LVFS values that were within a "normal" reference range; however, the mean LVFS was significantly lower than in control subjects. LVE relatives had a lower mitral S-wave velocity, prolonged time to peak S-wave velocity, and higher myocardial performance index, consistent with mild defects of LV systolic function. Indices of diastolic function were similar in LVE relatives and control subjects, with no augmentation of atrial contraction or rapid early filling that is characteristically seen in patients with established DCM and elevated LV filling pressure. The low mitral inflow E-wave velocity suggests normal LV filling pressure, consistent with normal levels of BNP in the majority of individuals. Despite the baseline impairment of systolic function as well as higher chamber volumes and heart rates, LVE relatives were able to partially compensate functionally to maintain cardiac output with exercise and achieved increments in systolic contraction and maximum heart rates similar to those in control subjects, explaining their lack of symptoms. However, the peak pulse pressure, rate-pressure product, and exercise duration were relatively reduced, consistent with blunting of peak myocardial work capacity.
Although statistically significant differences between groups were found for many of the functional parameters evaluated, there was a substantial scatter of data and overlap between LVE relatives and control subjects. To derive some practical guidelines for the investigation of individual family members, we determined the sensitivity and specificity of various parameters using data dichotomized Ϯ2 SD from mean values in control subjects. In this analysis, individual factors had low-to-moderate sensitivity and sensitivity. Surprisingly, the simple measures of LV dimensions and LVFS were more discriminative than the tissue Doppler and exercise echo parameters. Most of the individuals with abnormal tissue Doppler and exercise echo parameters were already identified by changes in LV dimensions and LVFS, and there was no incremental value for including these factors. Selecting individuals with more severe LV dilation [LVEDD (% predicted) Ͼ116%] or an intermediate extent of LV dilation, together with LVFS Ͻ2 SD from the control mean [LVEDD (% predicted) 112% to 116%ϩLVFS Յ29%], gave a very high sensitivity (100.0%) and specificity (93.3%) for differentiating LVE relatives from control subjects and identified 8 of the 9 progressors in the natural history study. These observations suggest that asymptomatic relatives that meet these criteria have a high likelihood of having early disease and warrant close-follow-up. In relatives with LVEDD (% predicted) 112% to 116%ϩLVFS Ͼ29%, some may be genotype-positive and too young to show signs of disease, whereas others may in fact be genotype-negative.
Identification of LVE relatives at greatest risk of progression remains a challenge. Although useful for detecting early disease, LVEDD (% predicted) Ͼ116% or LVEDD (% predicted) 112% to 116%ϩLVFS Յ29% had a positive predictive value of only 13% within a 5-year period. LVEDD and LVESD are independent predictors of congestive heart failure in a community-based population, 27 but we found no differences in the mean LVEDD or LVFS between progressors and nonprogressors at their baseline evaluation. Most of the diagnostic indices evaluated in the case-control study were not included in the natural history study, and hence we are unable to exclude the possibility that some of these may have a role in risk stratification or serial patient monitoring. Continued evaluation of markers of early disease is required, and techniques such as cine MRI may have a role in detecting and monitoring preclinical LV dysfunction. 28 A limitation of our study is the small number of genotyped individuals, and we cannot exclude the possible confounding effects of inclusion of some relatives with nongenetic causes of LVE. Because mutations in known disease genes are present in a minority (Ͻ25%) of DCM families, 3 the practical reality is that most physicians are required to assess family members who have unknown genotypes. Even if the genotype is known, there will be diverse underlying molecular defects, unique individual profiles of background genetic and environmental factors, and relatives are likely to be screened at varying temporal stages of the disease process. Hence, a functional classification of early disease may be more clinically useful than genotype per se.
These observations highlight the importance of clinical screening of asymptomatic relatives in DCM families and of ongoing follow-up for those with LVE. Accurate identification of high-risk subgroups within LVE cohorts will not only have implications for individual patient treatment but will also help to define a target study group for clinical trials. The ultimate goal of detection of early disease is preventative intervention, but there are currently no data to support either pharmacological treatment or wait-and-see approaches for presymptomatic family members. Prospective studies are urgently required to determine the most effective agents and optimal timing of prophylactic therapy.
